Creative Planning boosted its position in Viking Therapeutics Inc (NASDAQ:VKTX) by 600.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 70,000 shares of the biotechnology company’s stock after purchasing an additional 60,000 shares during the quarter. Creative Planning owned approximately 0.20% of Viking Therapeutics worth $284,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Sabby Management LLC purchased a new stake in shares of Viking Therapeutics in the second quarter worth $525,000. Sphera Funds Management LTD. purchased a new stake in shares of Viking Therapeutics in the third quarter worth $554,000. Virtu KCG Holdings LLC purchased a new stake in shares of Viking Therapeutics in the second quarter worth $124,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Viking Therapeutics in the third quarter worth $108,000. Institutional investors and hedge funds own 5.05% of the company’s stock.
Viking Therapeutics Inc (NASDAQ VKTX) traded down $0.21 during trading on Tuesday, hitting $6.14. The company had a trading volume of 1,506,800 shares, compared to its average volume of 1,611,857. Viking Therapeutics Inc has a 12 month low of $0.88 and a 12 month high of $7.15.
A number of equities research analysts have recently commented on VKTX shares. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Viking Therapeutics in a research note on Friday, November 10th. Roth Capital started coverage on Viking Therapeutics in a research note on Tuesday, November 21st. They issued a “buy” rating and a $5.00 target price on the stock. Maxim Group set a $8.00 target price on Viking Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, December 12th. BidaskClub raised Viking Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 7th. Finally, ValuEngine cut Viking Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $7.00.
TRADEMARK VIOLATION WARNING: “Viking Therapeutics Inc (VKTX) Position Raised by Creative Planning” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/13/creative-planning-has-284000-stake-in-viking-therapeutics-inc-vktx.html.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.